Clinical trials: Glaucoma
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit.
- Trial name
- NCT00143208
- Testing
- Xalacom
- Where
- 21 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00159653
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 55 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Glaucoma
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.
- Conditions
- Ocular Hypertension, Glaucoma, Open-angle Glaucoma
- Trial name
- NCT00856622
- Testing
- i. Fixed combination of latanoprost 0.005% and timolol 0.5%, timolol 0.5% ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 37 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Primary Open Angle Glaucoma
IOP and Medication Reduction in MIGS Procedures
The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
- Trial name
- NCT04202510
- Testing
- Glaucoma and Cataract Surgery
- Where
- United States
- Sponsor
- Wills Eye
Glaucoma, Open Angle, Ocular Hypertension
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure…
- Trial name
- NCT00140049
- Testing
- Xalacom, Cosopt
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open Angle, Ocular Hypertension
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
- Trial name
- NCT00219596
- Testing
- Xalacom, unfixed Latanoprost and Timolol
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Glaucoma
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
- Trial name
- NCT00800267
- Testing
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Where
- 53 sites in United States
- Volunteers
- 418 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-angle
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
- Trial name
- NCT00801437
- Testing
- Xalacom
- Where
- 39 sites in Slovakia
- Volunteers
- 457 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Efficacy and Safety of Non-resorbable Uveoscleral Implant Versus Absorbable Collagen Matrix in Non-perforating Deep Sclerectomy
The aim of the study is to evaluate and compare the hypotensive efficacy at 24 months between non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix versus…
- Trial name
- NCT04586738
- Testing
- non-perforating deep sclerectomy surgery
- Where
- 2 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Germans Trias i Pujol Hospital
Glaucoma
Optic Nerve Head Shape as a Predictor of the Formation of Acquired Pits of the Optic Nerve (APONs)
Acquired pits of the optic nerve (APONs) are an area of focal loss of neural tissue associated with a discrete area of depression/excavation within the optic cup at the level of the lamina cribrosa.
- Trial name
- NCT04610008
- Testing
- No intervention. Purely observation
- Where
- United Kingdom
- Volunteers
- 91 people
- Sponsor
- Cardiff and Vale University Health Board
Open Angle Glaucoma
MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
The study will evaluate the efficacy and safety of the implant and intra-ocular pressure (IOP) lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery.
- Trial name
- STAR-I (NCT03193736)
- Testing
- MINIject implant
- Where
- 2 sites in India, Panama
- Volunteers
- 26 people
- Sponsor
- iSTAR Medical
Open Angle Glaucoma
STARflo European Safety and Efficacy Study
Prospective, Non-comparative, Multi-center clinical trial to evaluate the safety and efficacy of the STARflo Glaucoma Implant in patients with refractory open angle glaucoma.
- Trial name
- NCT02272569
- Testing
- STARflo Glaucoma Implant
- Where
- 8 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 42 people
- Sponsor
- iSTAR Medical
Hemianopia, Hemianopsia
Collision Warning Device for Blind and Visually Impaired
This study evaluates a novel collision warning device to help people with severe vision impairment or blindness avoid collisions with obstacles.
- Conditions
- Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness
- Trial name
- NCT03057496
- Testing
- Collision warning device
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Glaucoma, Eye Yoga
Training of Eye Movements in Glaucoma
The aim of the trial is to investigate the possibilities of improving visual impairments with eye training exercises (eye-yoga) in a total of 40 patients with glaucoma who have not previously been treated within a similar…
- Trial name
- EyeYoga (NCT04037384)
- Testing
- Eye yoga, Passive Reading
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Magdeburg
Glaucoma, Ocular Hypertension
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control…
- Trial name
- NCT04743622
- Testing
- Monoprost, Xalatan
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- CHA University
Ocular Hypertension, Glaucoma
Foot Reflexology in Ocular Hypertensive and Glaucoma Patients
To determine the effect of foot reflexology in primary open angle glaucoma (POAG) patients and the effect of a shoe insert to perform continuous foot reflexology in ocular hypertensive (OHTN) patients.
- Trial name
- NCT04695314
- Testing
- Massage, Experimental insert
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Temple University
Glaucoma, Primary Open Angle
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a…
- Trial name
- NCT04737928
- Testing
- Latanoprost, tafluprost
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD